Insulet is delivering strong Omnipod growth, expanding margins, and rising EPS, but management is already signaling slower growth ahead. The stock looks attractive for long-term investors, though valuation leaves less room for error.
Insulet Corporation (PODD) combines a recurring consumables model, strong automated insulin delivery growth, and expanding profitability. Q3 2026 revenue reached $842.0M, up 19.2% year over year, while adjusted EPS rose 59.9% to $1.99. The investment case rests on Omnipod's tubeless design, a customer base growing more than 20%, and a pipeline led by Omnipod 6 and fully closed-loop delivery for type 2 diabetes.
The main issue is not demand today. It is the durability of growth after an exceptionally strong base year. Management expects 2026 revenue growth of 21% to 22%, but described 2027 growth as modestly below its prior mid-teens framework because of tougher international comparisons, new competition, and the timing of product launches. That makes PODD a high-quality growth business, but not a low-risk one.
For a moderate-risk investor with a medium-term horizon, the balance favors a Buy rating. Revenue growth, gross margin expansion, eight consecutive quarterly EPS beats, and a 7.5% free cash flow yield provide substantial support. The valuation already reflects much of the company's quality, so entry price still matters.
Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its core platform is Omnipod, a disposable, tubeless pump that delivers insulin through a wearable pod rather than a conventional pump and infusion tube. The company also manufactures pods for Amgen's Neulasta Onpro system, although that business is small relative to Omnipod.
The business is built around repeat pod purchases. Omnipod products are worn for up to three days, which creates recurring revenue after a patient starts therapy. Insulet sells through the pharmacy channel, wholesalers, distributors, and direct channels. Its 2025 Form 10-K stated that 86% of global Omnipod sales moved through intermediaries, while three distributors represented 27%, 26%, and 25% of revenue.
Insulet employed approximately 5,400 people at the latest company profile and is headquartered in Acton, Massachusetts. Ashley A. McEvoy serves as president and CEO, and Flavia H. Pease serves as executive vice president and CFO. The company operates in the United States and international markets, with Omnipod products available in 25 countries according to the 2025 10-K.
Insulet's operating profile is overwhelmingly an Omnipod story. In Q3 2026, total Omnipod revenue was $836.6M, or nearly all of the $842.0M company total. Drug Delivery revenue was $5.5M, down 22.7% year over year, reinforcing that the Amgen-related business is an ancillary activity rather than a second growth engine.
U.S. Omnipod revenue was $570.4M in Q3, up 14.7%. The U.S. customer base grew in the high teens, but new customer starts were flat year over year. Pricing was slightly lower during the quarter and flat year to date. Management's full-year U.S. Omnipod growth outlook is 17.5% to 18.5% on a constant-currency basis.
International Omnipod revenue was $266.2M, up 31.7% reported and 33.0% in constant currency. Volume drove most of the increase, with favorable price mix also contributing. Management expects international Omnipod growth of 32% to 33% in 2026, although it expects international growth to moderate in 2027 after major country launches and strong price mix benefits.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Omnipod 5 is the flagship product and the center of Insulet's competitive position. It combines a wearable pod, an embedded automated insulin delivery algorithm, and continuous glucose monitor integration. The system currently works with selected Dexcom and Abbott sensors and can be controlled through an Insulet handheld device or compatible smartphone applications.
The product addresses a practical problem: intensive insulin therapy requires frequent decisions and injections. The Omnipod device can be worn on the abdomen, hip, back of the upper arm, upper thigh, or lower back. It is waterproof to 25 feet for up to 60 minutes and provides automated cannula insertion. These details matter because convenience and lifestyle fit rank among the most important factors in patient AID selection.
Insulet expanded Omnipod 5's capabilities with a lower 100 mg/dL target setting and fewer automated delivery restriction alarms. Management said real-world evidence showed more time in range without a meaningful increase in low glucose events. The company also completed the full U.S. market release of Omnipod Discover, which had reached more than 35,000 users and 5,000 clinicians by the November 4, 2026 earnings call.
Omnipod 6 is expected to launch in 2027 after Insulet submitted the second and final 510(k) application. The product is designed to reduce user burden, and its launch timing is central to the 2027 growth outlook. A fully closed-loop system for type 2 diabetes is targeted for 2028, with no user-initiated boluses or settings required and home training designed to take less than 40 minutes.
Insulet's moat is a combination of product design, data, manufacturing scale, and customer experience. The tubeless form factor is a clear physical distinction from traditional tubed pumps. The recurring pod model then converts that product distinction into repeat purchases, while smartphone control and CGM integration keep the platform connected to a broader digital ecosystem.
The data layer is becoming more important. Insulet said its products make more than 100 million automated dosing decisions and process more than 850 million data messages each day. Omnipod Discover uses this data to provide insights and decision support. During its limited market release, 75% of users reported greater confidence managing diabetes, while management reported stronger retention and improved time in range.
Insulet had more than 1,000 issued patents and more than 700 pending patent applications as of December 31, 2025. The portfolio covers the pod drive system, cannula insertion, software, algorithms, applications, and user interfaces. The company also reported that Omnipod was the leading AID choice among providers and people with diabetes in a survey across six countries.
The competitive advantage is reinforced by customer behavior. More than 85% of new Omnipod starts come from multiple daily injection therapy, and management stated that people who convert to AID are unlikely to switch brands. That creates a valuable conversion funnel, although it also makes onboarding and retention execution important.
Insulet manufactures at highly automated facilities in Acton, Massachusetts, and Johor, Malaysia. It is investing in a third facility in Costa Rica and also uses a contract manufacturing facility in China for certain products. This network supports production of tens of millions of pods per year and gives the company capacity to serve a growing installed base.
Q3 2026 adjusted gross margin was 74.2%, up 200 basis points year over year. Management attributed the improvement to productivity gains and manufacturing scale. The margin result is a useful operating proof point: higher pod volumes are not merely producing revenue growth, they are also improving the economics of each dollar of sales.
Commercial execution is expanding alongside factory capacity. Insulet increased its U.S. sales force footprint by nearly 25% in Q3, introduced a new CRM platform, and added clinical specialists focused on retention. Nearly 34,000 U.S. healthcare providers prescribed Omnipod, up more than 20% year over year.
The supply chain still has concentrated dependencies. The 2025 10-K identified limited or single-source suppliers for specialized components such as application-specific integrated circuits, Bluetooth chips, and other proprietary parts. Insulet holds inventory internally and at suppliers to reduce disruption risk, but the concentration remains a meaningful operational consideration.
The market opportunity is large because insulin pump adoption remains incomplete. Insulet estimates approximately 6 million people with type 1 diabetes in the countries it serves and approximately 6 million people with insulin-requiring type 2 diabetes. It also estimates another 3 million U.S. type 2 patients use basal insulin only.
Pump penetration leaves room for conversion. Approximately 40% of the U.S. type 1 population and 25% of the international type 1 population use pump therapy, while penetration among insulin-requiring type 2 patients is smaller. The company's 2025 Investor Day described a $30B-plus addressable market across approximately 8 million people with diabetes, with the AID market estimated at roughly $6B and projected at approximately $9B by 2028.
Industry adoption is moving toward automated systems that integrate CGMs, algorithms, and mobile software. The American Diabetes Association's 2026 standards identified AID as the preferred insulin delivery method over MDI, conventional pump therapy, and sensor-augmented pumps for relevant insulin-treated populations. This supports a shift from injection conversion toward automated therapy adoption.
Insulet's strongest market indicators are its installed-base growth and conversion mix. The global customer base grew more than 20% year over year in Q3, and more than 85% of new starts came from MDI. That is evidence that the company is expanding the pump category rather than relying only on customers switching from another pump maker.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The core customer is a person with insulin-dependent diabetes who values fewer injections, discreet wearability, and automated glucose management. Omnipod 5 serves both type 1 and type 2 users. In Q3, people with type 2 diabetes represented more than 40% of U.S. new starts, giving Insulet an important expansion path beyond its traditional type 1 base.
Customer acquisition depends on three groups: patients, healthcare providers, and payors. Insulet reported Omnipod awareness among MDI users of 67% in the United States, 84% in the United Kingdom, and 74% in Canada. Its sales organization also focuses on clinical evidence, provider education, reimbursement support, and onboarding.
Retention is especially important because pod purchases recur throughout the customer relationship. Insulet reported a modest improvement in type 2 retention in Q3 after changing sales compensation, refining samples, improving onboarding, and adding customer-care specialists. The result is encouraging, but the company remains dependent on consistent service and product reliability to protect the recurring revenue base.
Insulet competes with Medtronic Diabetes, Tandem Diabetes Care, Beta Bionics, Ypsomed, and other patch-pump developers. It also competes indirectly with MDI products, smart insulin pens, and medication-based treatment. In the U.S. type 1 pump market, Medtronic, Tandem, and Insulet collectively hold approximately 96% share according to a peer filing.
PODD's central differentiation is the tubeless disposable architecture. Tandem and Medtronic have established installed bases and broad AID capabilities, but their traditional pump designs do not offer the same tubeless user experience. Beta Bionics adds a credible AID competitor, while Ypsomed and other patch-pump developers increase the pressure on form factor, interoperability, and price.
Medtronic announced on May 21, 2025 that it intended to separate its diabetes business into MiniMed. A more focused MiniMed could sharpen competitive execution. Insulet's counterweight is scale: management said the company has the largest customer base, high brand awareness, one of the largest real-world diabetes datasets, and a manufacturing footprint built over decades.
Insulet operates in a regulated medical-device market. U.S. products require FDA clearance or approval, and post-market requirements cover manufacturing quality, labeling, adverse-event reporting, recalls, and surveillance. Omnipod 6 is therefore subject to both product-development execution and regulatory timing risk, even though the company has submitted its final 510(k) application.
Reimbursement is another macro variable. Omnipod products are sold through commercial insurance, Medicare, Medicaid, and international healthcare systems. Insulet finalized one of three U.S. PBM contracts for 2027 during Q3 and was working through the remaining contracts. Broad pharmacy access supports adoption, while payer terms can influence pricing and customer acquisition.
Foreign exchange helped the 2026 outlook. Management expects currency to add approximately 100 basis points to total company growth and approximately 300 basis points to international growth. That benefit is financial rather than structural, so the underlying volume performance matters more for the medium-term thesis.
GLP-1 drugs create a mixed backdrop. The 2025 10-K identified the possibility that GLP-1 use could delay progression to insulin therapy for some type 2 patients. In Q3, management said it had not observed an impact from increased GLP-1 use on type 2 new starts and viewed GLP-1 treatment as complementary to insulin. Both facts belong in the risk analysis.
Insulet's balance sheet supports the story, with a B+ rating and enough financial flexibility to back continued Omnipod investment while growth remains strong.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q3 2026 revenue rose 19.2% to $842.0M and adjusted EPS jumped 59.9% to $1.99, underscoring the company’s accelerating profitability.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management still expects 2026 revenue growth of 21% to 22%, but 2027 is already being framed as modestly below the prior mid-teens growth framework.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Insulet’s valuation earns a B, reflecting a premium growth profile that is partly offset by slower growth expectations and a 7.5% free cash flow yield.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework points to a $180 fair value, with the Buy case supported by growth, margin expansion, and eight straight quarterly EPS beats.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Insulet is one of the stronger growth stories in medical devices. Q3 2026 delivered $842.0M of revenue, 22.5% operating margin, $141.1M of net income, and $2.03 of reported EPS. The company has also beaten EPS estimates in eight consecutive quarters, expanded its customer base more than 20%, and maintained a product architecture that is difficult to replicate quickly.
The investment case is strongest when viewed as a platform rather than a single pump. Omnipod 5 drives recurring pod revenue today, Omnipod Discover adds a data and engagement layer, Omnipod 6 provides a 2027 product catalyst, and fully closed-loop type 2 delivery extends the addressable market. Manufacturing scale and CGM compatibility add further support.
The risks are equally concrete: debt still exceeds cash, distributor concentration is high, specialized components include single-source dependencies, and management expects growth to moderate in 2027. Competition from Medtronic, Tandem, Beta Bionics, Ypsomed, MDI alternatives, and GLP-1 therapies will keep the market demanding. Those risks support a Buy rating rather than a Strong Buy rating.
PODD offers a credible path to wealth creation through category expansion, recurring consumables, and operating leverage. The disciplined approach is to own the business, respect the valuation, and add more aggressively at the lower target levels.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Insulet's 20.12% selloff reflects a credibility hit to its U.S. growth engine, not merely a disappointing trading session. The FY2026 guidance cut makes the Omnipod runway harder to underwrite, even after a strong Q2 and continued international expansion.
Insulet is delivering strong Omnipod-driven growth, with Q1 revenue up 33.9% and guidance raised for 2026. The stock looks attractive for growth investors, but its premium valuation and execution risk keep the case from being low-risk.
Insulet beat on EPS and revenue, lifted full-year guidance, and still saw PODD drop sharply. This deep-dive looks beyond the headline beat to examine Omnipod growth, margin expansion, guidance nuance, and why investors focused on valuation and reaction rather than the strong quarter.